Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

July 19, 2023

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

July 19, 2023

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

July 12, 2023

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

July 12, 2023

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

July 05, 2023

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

July 05, 2023

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

July 04, 2023

Closing out their discussion on biliary tract cancers, Milind Javle, MD, and Laura Goff, MD, highlight current treatment guidelines and unmet needs as the landscape continues to evolve.

July 04, 2023

Expert perspectives on the KEYNOTE-966 and IMbrave151 clinical trials and novel chemoimmunotherapy combination strategies in biliary tract cancers.

July 03, 2023

Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.

June 28, 2023

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

June 28, 2023

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

June 27, 2023

Centering discussion on data from TOPAZ-1, Milind Javle, MD, and Laura Goff, MD, reflect on the value of chemoimmunotherapy combinations in biliary tract cancer management.

June 27, 2023

Drs Javle and Goff review standard of care treatment strategies for the management of biliary tract cancer and discuss recent NCCN guideline updates for the combination of durvalumab + cisplatin + gemcitabine.

June 21, 2023

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

June 21, 2023

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

June 20, 2023

Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.

June 20, 2023

Expert oncologists Milind Javle, MD, and Laura Goff, MD, reflect on the subsets of biliary tract cancers and consider best practices in making an accurate diagnosis.

June 15, 2023

First-line treatment with toripalimab in combination with gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs placebo plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma.

June 14, 2023

Megan M. Dupuis, MD, shares the complex journey she traveled during medical training and how it brought her to the academic setting.

June 12, 2023

Bhagirathbhai Dholaria, MBBS, discusses additional 10-month follow-up data from the phase 1 TRIMM-2 trial of subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma.